BTKi in Chemotherapy Improves Richter Transformation Outcomes in CLL
Okay, here’s a breakdown of the provided text, focusing on key information and summarizing the study described:
Main Topic: A study investigating the use of BTK inhibitors (BTKis) in combination with standard chemotherapy (CIT) for patients with Richter Transformation-Diffuse Large B-cell Lymphoma (RT-DLBCL).
Key Points:
* Richter Transformation (RT): RT-DLBCL is a notably aggressive form of lymphoma that develops in patients with Chronic Lymphocytic Leukemia (CLL). It has poorer outcomes than de novo (newly developed) DLBCL.
* Standard Treatment (CIT): Conventional chemotherapy regimens like R-CHOP frequently enough have limited success in RT-DLBCL.
* BTK Inhibitors (BTKis): These drugs have shown promise in treating CLL and some activity in RT-DLBCL, prompting the study.
* Study Design: Researchers at UCSF retrospectively analyzed medical records of 56 patients with RT-DLBCL (diagnosed 2012-2024).They excluded patients who had previously received BTKi therapy.
* Outcomes Measured:
* Objective Response Rate (ORR): the percentage of patients who showed a reduction in tumor size.
* Complete Response (CR): The percentage of patients who had no detectable signs of cancer.
* Overall survival (OS): The length of time patients survived after diagnosis.
* Key Findings:
* Overall: ORR was 62.5%,CR was 57.1%, and median OS was 57.2 months (better than many historical reports).
* BTKi combination: Patients who received CIT plus a BTKi (concurrently or with maintenance) had considerably better outcomes:
* 100% achieved CR (compared to 58.3% with CIT alone).
* The difference in CR rates was statistically significant.
In essence, the study suggests that adding a BTKi to frontline chemotherapy may substantially improve outcomes for patients with RT-DLBCL.
sources Cited:
* ASH Publications article on Richter Transformation: https://ashpublications.org/hematology/article/2023/1/427/506445/Richter-transformation-is-there-light-at-the-end
* Blood article on Outcomes of patients with Richter transformation: https://ashpublications.org/blood/article/146/Supplement%201/2110/552197/Outcomes-of-patients-with-Richter-transformation
Let me know if you’d like me to elaborate on any specific aspect of this information!